Searching for a cure, Improving lives




The computer on which the Registry service runs is sited in a secure data centre. This data centre features resilient infrastructure, including multiple levels of 24/7 security, stable high-capacity power supplies, redundant storage, multiple peering arrangements, fire protection, environmental controls and on-site support.  The service is managed via secure internet connections, with physical as well as software security enabling access to only authorised personnel. It is password protected and has a firewall. The service is managed and supplied by Nvisage Ltd. and their authorised partners on behalf of Action Duchenne Ltd. The Registry is regularly backed up to prevent loss of data.




The Registry is controlled by Action Duchenne Ltd in compliance with the Data Protection Act (1998).


Confidentiality of Records


We will keep your data private and secure. Your data is protected under the Data Protection Act (1998). Unauthorised third party access will not be allowed. Results of research carried out using anonymised data from the Registry may be presented at meetings or in publications. Your health information will be accessed to help research and possibly to develop or plan new test procedures, treatments or products. Health information may be used to report results of research to sponsors and regulators. It may be audited by regulators to make sure that we are following regulations, policies and plans. In these circumstances the information will be accessed anonymously.


Ethical Approval 


Any research that uses the Registry must have been passed by a medical ethics authority (e.g. COREC in the UK) that is regulated by the EU Clinical Trials Directive 2001, or a non-medical ethical authority (e.g. a university ethical committee) that has been approved by our Steering Committee.




Support Action Duchenne with a monthly or one off donation



View our events

View All Events


Join the DMD registry for access to clinical trials


Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD

March 27th, 2017

  Introduction from Michelle Avery (Summit Therapeutics): Today, we’ve announced that we intend to proceed

Tell me more

Amazing London Marathon Dinner at Jamie’s Italian!

February 7th, 2017

  On Saturday 3 February Andrew Parkinson and Andrew Pearson, two of our London Marathon

Tell me more

Positive Preclinical Research on the Edasalonexent (CAT-1004) Program

January 6th, 2017

  Catabasis announced the publication of preclinical data on the edasalonexent program, a potential disease-modifying

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne